Natco Pharma Ltd

Natco Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Natco Pharma Ltd

₹ 960 4.14%
03 Jul 1:25 p.m.
natcopharma.co.in BSE: 524816 NSE: NATCOPHARM
About

NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. [1]
NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.[2]

Key Points

Business Segments
1) Export Formulation (44% in Q3 FY25 vs 73% in FY23): [1] [2] The company manufactures and markets finished dosage formulations in 50+ countries, including the US, Canada, Brazil, and Europe. Major US partners include Sun-Ranbaxy, Aceto-Rising, Alvogen, Teva, Mylan, Actavis, Lupin, etc. Its international business focuses on Para IV and first-to-file molecules, with plans to expand into emerging markets like MENA, LATAM, and Southeast Asia. [3] [4]

Website BSE NSE
  • Market Cap ₹ 17,195 Cr.
  • Current Price ₹ 960
  • High / Low ₹ 1,639 / 660
  • Stock P/E 9.17
  • Book Value ₹ 425
  • Dividend Yield 1.02 %
  • ROCE 32.8 %
  • ROE 28.0 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 33.4% CAGR over last 5 years

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap Nifty Pharma

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
597 885 432 492 898 1,140 1,031 759 1,068 1,363 1,371 475 1,221
615 489 337 387 559 612 573 490 571 558 567 436 673
Operating Profit -19 395 95 106 339 528 458 268 497 805 804 39 548
OPM % -3% 45% 22% 22% 38% 46% 44% 35% 47% 59% 59% 8% 45%
14 34 20 21 29 20 29 37 42 48 64 176 66
Interest 7 4 4 4 3 4 4 5 6 5 4 4 10
Depreciation 38 40 42 42 41 44 44 44 56 44 46 47 98
Profit before tax -50 386 70 81 324 500 440 256 478 804 818 164 506
Tax % 2% 17% 19% 23% 15% 16% 16% 17% 19% 17% 17% 19% 20%
-50 320 57 62 276 420 369 213 386 668 676 132 406
EPS in Rs -2.77 17.55 3.11 3.41 15.11 23.47 20.60 11.88 21.57 37.32 37.81 7.43 22.70
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
739 825 1,042 2,020 2,185 2,094 1,915 2,052 1,945 2,707 3,999 4,430
560 615 777 1,337 1,256 1,300 1,332 1,446 1,681 1,772 2,245 2,234
Operating Profit 179 210 266 683 928 795 583 606 264 936 1,754 2,196
OPM % 24% 25% 25% 34% 42% 38% 30% 30% 14% 35% 44% 50%
17 0 12 14 40 130 107 104 99 105 126 354
Interest 37 32 23 18 15 19 22 13 18 14 19 24
Depreciation 30 47 51 54 66 81 100 117 143 164 187 235
Profit before tax 129 132 204 624 887 825 569 580 202 862 1,674 2,291
Tax % 24% 1% 24% 22% 22% 22% 19% 24% 16% 17% 17% 18%
98 130 156 485 695 642 458 442 170 715 1,388 1,883
EPS in Rs 6.21 8.10 9.02 27.88 37.74 35.24 25.31 24.18 9.31 39.18 77.51 105.26
Dividend Payout % 16% 12% 14% 24% 22% 18% 27% 22% 48% 14% 12% 6%
Compounded Sales Growth
10 Years: 18%
5 Years: 18%
3 Years: 32%
TTM: 11%
Compounded Profit Growth
10 Years: 30%
5 Years: 33%
3 Years: 139%
TTM: 35%
Stock Price CAGR
10 Years: 7%
5 Years: 7%
3 Years: 12%
1 Year: -24%
Return on Equity
10 Years: 19%
5 Years: 18%
3 Years: 24%
Last Year: 28%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 33 33 35 35 37 36 36 36 36 36 36 36
Reserves 693 813 1,261 1,614 3,035 3,452 3,737 4,085 4,227 4,837 5,817 7,571
240 312 113 222 173 386 316 268 416 167 371 279
229 226 413 446 470 428 498 403 430 617 682 744
Total Liabilities 1,196 1,384 1,822 2,318 3,715 4,303 4,588 4,792 5,109 5,657 6,906 8,631
645 710 710 833 1,019 1,227 1,584 2,023 2,312 2,427 2,491 2,698
CWIP 124 129 212 336 480 638 518 223 130 64 137 225
Investments 2 2 22 32 76 169 112 304 308 392 539 474
425 543 878 1,116 2,140 2,270 2,373 2,242 2,360 2,774 3,739 5,234
Total Assets 1,196 1,384 1,822 2,318 3,715 4,303 4,588 4,792 5,109 5,657 6,906 8,631

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
144 93 112 346 464 669 417 299 46 849 1,212 1,697
-108 -120 -176 -299 -1,116 -611 -175 -107 4 -465 -1,026 -1,414
-35 29 154 -48 651 -51 -251 -186 35 -363 -247 -211
Net Cash Flow 0 2 90 -1 -2 7 -8 6 85 21 -62 72

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 59 85 92 86 106 88 105 73 116 115 109 103
Inventory Days 283 331 482 213 389 545 534 570 496 432 357 405
Days Payable 172 189 372 160 239 224 244 104 105 153 120 145
Cash Conversion Cycle 170 228 202 138 257 410 395 539 507 394 345 362
Working Capital Days 71 99 131 111 244 275 355 294 335 220 184 200
ROCE % 18% 17% 18% 39% 35% 23% 14% 13% 4% 18% 30% 33%

Shareholding Pattern

Numbers in percentages

3 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
48.80% 48.80% 48.82% 48.84% 49.76% 49.71% 49.71% 49.71% 49.71% 49.62% 49.62% 49.56%
11.65% 11.67% 11.73% 11.91% 11.03% 12.82% 13.72% 16.14% 17.45% 17.51% 17.94% 17.49%
15.30% 14.30% 14.93% 15.38% 15.15% 14.01% 11.26% 9.69% 7.86% 6.75% 5.59% 5.64%
24.25% 25.23% 24.53% 23.87% 24.08% 23.48% 25.32% 24.46% 24.99% 26.13% 26.88% 27.30%
No. of Shareholders 92,4491,21,3361,35,3971,53,6631,55,1811,63,7532,07,5712,28,4672,51,4853,02,9443,45,3324,05,222

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls